KIN1148

Cas No.:	1428729-56-9
Chemical Name:	N-(Benzo[1,2-d:3,4-d']bis(thiazole)-2-yl)-2-naphthamide
Synonyms:	KIN1148;N-Benzo[1,2-d;N-(benzo[1,2-d:3,4-d']bis(thiazole)-2-yl)-2-naphthamide;N-([1,3]thiazolo[5,4-e][1,3]benzothiazol-2-yl)naphthalene-2-carboxamide;BCP29251;KIN 1148;AK688999
SMILES:	S1C(N([H])C(C2C([H])=C([H])C3=C([H])C([H])=C([H])C([H])=C3C=2[H])=O)=NC2C([H])=C([H])C3=C(C1=2)N=C([H])S3
Formula:	C19H11N3Os2
M.Wt:	361.4401
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.
In Vivo:	Prime-boost immunization of mice with a suboptimal dose of a monovalent pandemic influenza split virus H1N1 A/California/07/2009 vaccine plus KIN1148 protect against a lethal challenge with mouse-adapted influenza virus (A/California/04/2009) and induce an influenza virusspecific IL-10 and Th2 response by T cells derived from lung and lung-draining lymph nodes. Primeboost immunization with vaccine plus KIN1148, but not prime immunization alone, induce antibodies capable of inhibiting influenza virus hemagglutinin and neutralizing viral infectivity. Nevertheless, a single immunization with vaccine plus KIN1148 provide increased protection over vaccine alone and reduce viral load in the lungs after challenge[1].
In Vitro:	KIN1148 induces the dose-dependent nuclear translocation of IRF3 in PH5CH8 cells and specific activation of IRF3- responsive promoters. KIN1148 also elicits greater induction of endogenous IRF3-dependent ISG54 and OASL expression by PH5CH8 cells[1].